152 related articles for article (PubMed ID: 26023210)
1. Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?
López-Cortés LE; Velasco C; Retamar P; del Toro MD; Gálvez-Acebal J; de Cueto M; García-Luque I; Caballero FJ; Pascual A; Rodríguez-Baño J
J Antimicrob Chemother; 2015 Sep; 70(9):2652-60. PubMed ID: 26023210
[TBL] [Abstract][Full Text] [Related]
2. Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteraemia.
Viedma E; Sanz F; Orellana MA; San Juan R; Aguado JM; Otero JR; Chaves F
J Antimicrob Chemother; 2014 Jan; 69(1):51-8. PubMed ID: 23975741
[TBL] [Abstract][Full Text] [Related]
3. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy.
Gasch O; Camoez M; Dominguez MA; Padilla B; Pintado V; Almirante B; Molina J; Lopez-Medrano F; Ruiz E; Martinez JA; Bereciartua E; Rodriguez-Lopez F; Fernandez-Mazarrasa C; Goenaga MA; Benito N; Rodriguez-Baño J; Espejo E; Pujol M;
Clin Microbiol Infect; 2013 Nov; 19(11):1049-57. PubMed ID: 23331461
[TBL] [Abstract][Full Text] [Related]
5. No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia.
Bouiller K; Laborde C; Aho SL; Hocquet D; Pechinot A; Le Moing V; Bertrand X; Piroth L; Chirouze C
Int J Antimicrob Agents; 2018 May; 51(5):721-726. PubMed ID: 29305961
[TBL] [Abstract][Full Text] [Related]
6. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
[TBL] [Abstract][Full Text] [Related]
7. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
[TBL] [Abstract][Full Text] [Related]
9. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.
Mascitti KB; Edelstein PH; Fishman NO; Morales KH; Baltus AJ; Lautenbach E
Infect Control Hosp Epidemiol; 2012 Feb; 33(2):160-6. PubMed ID: 22227985
[TBL] [Abstract][Full Text] [Related]
10. Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.
Sullivan SB; Austin ED; Stump S; Mathema B; Whittier S; Lowy FD; Uhlemann AC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507105
[TBL] [Abstract][Full Text] [Related]
11. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
12. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus causing bacteraemia in Southern Spain.
Velasco C; López-Cortés LE; Caballero FJ; Lepe JA; de Cueto M; Molina J; Rodríguez F; Aller AI; García Tapia AM; Pachón J; Pascual A; Rodríguez-Baño J;
J Hosp Infect; 2012 Aug; 81(4):257-63. PubMed ID: 22738614
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Warren SJ; Gao W; Johnson PD; Howden BP
Clin Microbiol Infect; 2013 Dec; 19(12):1163-8. PubMed ID: 23441652
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
Baxi SM; Clemenzi-Allen A; Gahbauer A; Deck D; Imp B; Vittinghoff E; Chambers HF; Doernberg S
Antimicrob Agents Chemother; 2016 Sep; 60(9):5276-84. PubMed ID: 27324762
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant Staphylococcus aureus bacteraemia from 21 Spanish hospitals.
Gasch O; Camoez M; Dominguez MA; Padilla B; Pintado V; Almirante B; Martín-Gandul C; López-Medrano F; de Gopegui ER; Ramón Blanco J; García-Pardo G; Calbo E; Horcajada JP; Granados A; Jover-Sáenz A; Dueñas C; Pujol M;
Clin Microbiol Infect; 2014 Apr; 20(4):361-7. PubMed ID: 23991832
[TBL] [Abstract][Full Text] [Related]
17. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence.
Forstner C; Dungl C; Tobudic S; Mitteregger D; Lagler H; Burgmann H
Clin Microbiol Infect; 2013 Jul; 19(7):E291-7. PubMed ID: 23490021
[TBL] [Abstract][Full Text] [Related]
18. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
19. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
20. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
